Biomolecular Analysis for Predicting Response to Regorafenib
The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.
Glioblastoma|Glioblastoma, IDH-wildtype
DIAGNOSTIC_TEST: Biomolecular tumor analysis
Overall survival, Interval between tumor diagnosis and death or end of follow-up, through study completion, an average of 3 years
The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.